Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access VELCADE for relapsed or refractory multiple myeloma
2004-001178-13Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2004
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Johnson & Johnson. Primary endpoint: Access to VELCADE. Started Oct 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2004-001178-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001178-13.